MelliCell
About:
MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model weight gain in human fat cells in vitro.
Website: https://www.mellicell.com
Top Investors: National Science Foundation, National Institute of Diabetes and Digestive and Kidney Diseases
Description:
MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model weight gain in human fat cells in vitro. Founded in 2020, the company is headquartered in Newton, Massachusetts.
Total Funding Amount:
$3.17M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Newton, Massachusetts, United States
Founded Date:
2020-01-01
Contact Email:
info(AT)mellicell.com
Founders:
Ben Pope, Prince Nnah
Number of Employees:
1-10
Last Funding Date:
2024-10-24
IPO Status:
Private
Industries:
© 2025 bioDAO.ai